“Most social network founders want to make money. Ijad Madisch, the scientist-CEO behind ResearchGate, has a higher goal: He wants to win a Nobel Prize for the network.
Five years after its founding, Madisch’s plan doesn’t seem so far-fetched. ResearchGate, which has been described as “LinkedIn for scientists,” has 2.9 million users — about half of the international scientific community. Madisch has built a list of success stories in which scientists used ResearchGate to speed up their work. And as of now, he’s got a formidable supporter you may have heard of: Bill Gates.”
ORCID, an international, interdisciplinary, open and not-for-profit organisation, recently revealed information on what an ORCID identifier looks like.
The ORCID ID is a 16-digit number that is compatible with the ISO Standard (ISO 27729), also known as the International Standard Name Identifier (ISNI). Initially, ORCID IDs will be randomly assigned by the ORCID Registry from a block of numbers that will not conflict with ISNI-formatted numbers assigned in other ways. ORCID IDs always need all 16-digits – they cannot be shortened to remove leading zeros if they exist.
Only the ORCID Registry will assign ORCID IDs, either through the ORCID website, or the related APIs. ORCID IDs are intended to be assigned to individuals, and may be secured at no charge. The IDs will be assigned randomly from a block of numbers reserved for this purpose. (Initially IDs will be assigned between 0000-0001-5000-0000 and 0000-0003-5000-000X).
ORCID IDs will be expressed as an HTTP URI. The number will be proceeded by ‘http://orcid.org/‘. A hyphen will be inserted every 4 digits to aid readability, though if the hyphens are removed, the number still refers to the same ORCID ID.”
Many U.S. funding agencies are now requiring researchers to submit a data management plan with their grant applications. DMPTool* provides guidance in creating ready to use data management plans for:
NIH, NEH, NOAA, NSF, Gordan and Betty Moore, IMLS
The tool has been customized for Princeton users. Log in with your Princeton NetID for additional Princeton specific help links and suggested text for researchers who will be using the DataSpace repository. Simply select Princeton University and log in with your Princeton netID and password.
Want to learn more?
View a brief video demonstration of the tool at https://dmp.cdlib.org/help/video_demo
*DMPTool was developed by DataONE, Digital Curation Centre (UK), Smithsonian Institution, UC Curation Center, California Digital Library, UCLA Library, UC San Diego Libraries, University of Illinois, and University of Virginia Libraries.
The nerve center of Nimbus Discovery, a largely virtual biotech start-up, resides in the offices of Atlas Venture in Cambridge, MA. Bruce Booth, an Atlas partner and chairman of the small company, recently to talked to me at the firm’s offices about how Nimbus is making use of computer-aided drug discovery software from Schrödinger to advance a pipeline of potential treatments for cancer, obesity other conditions.
Microsoft ($MSFT) chairman Bill Gates was announced as one of Nimbus’ seed investors in March, raising the profile of the young firm and shedding light on its unique relationship with Schrödinger, in which Gates invested last year through his Cascade Investment group. Nimbus hasn’t disclosed how much it has brought from Gates, Atlas and its other seed investors, yet more details could be in the offing; the company is planning a Series A round of funding in the near future.
Schrödinger, a global provider of chemistry simulation software for pharmaceutical companies, is a major shareholder in Nimbus. Ramy Farid, Schrödinger’s president, co-founded Nimbus with Atlas’ Booth in 2009 and sits on its board, the chairman says. The start-up has special access to Schrödinger’s software, support from the 21-year-old company’s computational chemistry experts and business expertise from Atlas.
While it’s too early to say with Nimbus’ drugs will succeed in clinical trials, the upstart has been able to show how the use of new software for understanding disease proteins and other tools have helped speed its drug discovery efforts, according to Booth. Read the full article >>“
“The PubMed Abstract display for PubMed Central® articles will be enhanced to include an image strip generated from the soon-to-be-released National Center for Biotechnology Information (NCBI) Images database.” To see an example, click on the linked article below:
August 30, 2010 — A new report from the InterAcademy Council, an organization of the world’s science academies, including the U.S. National Academy of Sciences, says that the process used by the Intergovernmental Panel on Climate Change to produce its periodic assessment reports has been a success overall, but that IPCC needs to reform its management structure, strengthen its procedures, and become more transparent to handle increasingly complex climate assessments and greater public scrutiny. The report was released today at the United Nations.
The debate continues over whether cloud platforms can secure highly sensitive clinical trial data and health records. But eWeek makes no bones about its position in a top 10 list of why it’s a bad idea to store such records up there.
The 11-slide presentation encapsulates both well-known and less-well-known arguments for data storage via local services rather than an Internet-based, on-demand system. Among them: the highly sensitive nature of the data makes it a hacker target from the get-go.
Trust is a factor that runs throughout the list: trust in the cloud service provider that it can and will restrict access to the barest minimum, that it truly de-personalizes data, and even that it will still be in existence tomorrow.
A disclosure statement concerning source material explains the anti-cloud bias. But the list remains a useful one.
The Royal Society of Chemistry (RSC), UK, has announced the release of ChemSpider SyntheticPagesbeta, a community resource of reaction synthesis procedures. The launch of a beta site is the result of a collaboration between ChemSpider, a free online structure centric community for chemists, and the original SyntheticPages. SyntheticPages is a freely available interactive database of synthetic chemistry for the dissemination of practical and reliable organic, organometallic and inorganic chemical synthesis, reactions and procedures deposited by synthetic chemists.
Under the partnership, ChemSpider will host content from SyntheticPages. A search of ChemSpider SyntheticPagesbeta allows identification and detailing of the experimental procedures for the synthesis of specific chemical compounds. The database has been seeded with SyntheticPages.org data and will be expanded by inclusion of data from journal articles published by RSC.
Researchers will also be able to deposit their own synthetic procedures to the site. Using online semantic markup technologies and integrating to the ChemSpider database will allow interactive display of chemical structures, spectral data and a multitude of related data. Scientists can comment upon a growing resource of interactive synthetic processes, while leveraging the resources contained within the ChemSpider databases.